Study of pretreatment serum levels of HER-2/neu oncoprotein as a prognostic and predictive factor in patients with advanced nonsmall cell lung carcinoma.

摘要: BACKGROUND HER-2/neu tissue overexpression is found in nearly 15% of patients with nonsmall cell lung carcinoma and reported to affect prognosis adversely surgical series. However, the prognostic role serum HER-2/neu oncoprotein, particularly advanced carcinoma, remains unknown. This study was designed assess potential value measuring levels oncoprotein predicting response treatment survival locally metastatic carcinoma. METHODS Baseline (fm/mL) were studied using an enzyme-linked immunosorbent assay method 84 newly diagnosed, who underwent chemotherapy. RESULTS The enrolled included 76 males 8 females, a median age 62 years (range, 36–73 years) performance status 1. Fifty (59.5%) had nonsquamous histology, 34 (40.5%) squamous carcinoma. Thirty-four Stage III disease, 50 IV disease. The mean baseline whole series 56.1 fm/mL 13.0–103.8 fm/mL). HER2 immunohistochemistry on paraffin embedded performed 18 patients. only one patient, also showed high (102 No correlation observed between protein quantitation gender, age, stage, status, leukocyte count, or smoking. Nonresponding responding exhibited similar (median, 57.6 vs. 51.9 fm/mL, respectively). overall rate 42.5% at 1 year 12% 2 years, duration 10 months. At univariate analysis, associated unfavorable outcome. Using cut-off point for 73.0 (corresponding 80th percentile concentration), higher significantly worse compared lower 7.1 months 10.9 months; P = 0.004). Multivariate analysis confirmed independent predictive concentration as negative factor (P 0.02). CONCLUSIONS High pretreatment are adverse impact Cancer 2001;92:1896–904. © 2001 American Society.